"Zentalis reported significant progress in the development of azenosertib in 2024 and made important advancements this year. We plan to maintain strong execution on the late-stage development of ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in ...

Continue advancement of MRT-6160 through Phase 2 initiation, in collaboration with Novartis. Share additional MRT-2359 Phase 1/2 study data in ...

Genentech Inc. has disclosed molecular glue compounds with the ability to induce cyclin-dependent kinase 2 (CDK2)/protein cereblon (CRBN) interaction for CDK2 degradation reported to be useful for the ...

WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader, NKT3964, by completing the dosing of the first patient cohort in a ...

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate ...

NiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for treating adults with advanced or metastatic solid tumours. The dose-escalation ...

通过下调细胞周期相关蛋白（CDK2和Cyclin D1/E1）阻止结直肠癌细胞进入S期，进而阻止细胞增殖。在HCT-116细胞中（早期阶段），阿魏酸主要作用于G1期 ...

We simulated entry into G2 by a step change of cdk2-cyclin A activity from 0 to a positive value, and ran simulations at 0%, 50%, 90%, and 100% plk1 inhibition to recapitulate our BI2536 dose-response ...

A computational model explains the variable delay in mitotic entry We simulated entry into G2 by a step change of cdk2-cyclin A activity from 0 to a positive value, and ran simulations at 0%, 50%, 90% ...